Bevacizumab versus anti–epidermal growth factor receptor in first-line metastatic colorectal cancer. A meta-analysis: The last building block?

This publication has 8 references indexed in Scilit:

• A study-level meta-analysis of efficacy data from head-to-head first-line trials of epidermal growth factor receptor inhibitors versus bevacizumab in patients with RAS wild-type metastatic colorectal cancer
  European Journal of Cancer, 2016
• FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial
  The Lancet Oncology, 2016
• ESMO consensus guidelines for the management of patients with metastatic colorectal cancer
  Annals of Oncology, 2016
• Role of First-Line Anti–Epidermal Growth Factor Receptor Therapy Compared With Anti–Vascular Endothelial Growth Factor Therapy in Advanced Colorectal Cancer: A Meta-Analysis of Randomized Clinical Trials
  Clinical Colorectal Cancer, 2015
• FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial
  The Lancet Oncology, 2014
• PEAK: A Randomized, Multicenter Phase II Study of Panitumumab Plus Modified Fluorouracil, Leucovorin, and Oxaliplatin (mFOLFOX6) or Bevacizumab Plus mFOLFOX6 in Patients With Previously Untreated, Unresectable, Wild-Type KRAS Exon 2 Metastatic Colorectal Cancer
  Journal of Clinical Oncology, 2014
• PROSPERO at one year: an evaluation of its utility
  Systematic Reviews, 2013
• Meta-analysis of the literature or of individual patient data: is there a difference?
  The Lancet, 1993